Summit Therapeutics Inc. (SMMT) Stock
SMMT has an Alpha Score of 40 out of 100 (weak), computed on Apr 15, 2026 from 3 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported SMMT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $53.88M.
What is SMMT's Alpha Score?
How it works →Alpha Score of 40 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Apr 15, 2026 · 189 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own SMMT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 3.70M | $53.88M | +372% |
| Millennium Management Israel Englander | 2.35M | $34.23M | +1760% |
| Citadel Ken Griffin | 1.73M | $25.14M | +291% |
| D.E. Shaw David Shaw | 1.24M | $18.12M | -45% |
| Marshall Wace | 577K | $8.41M | +21% |
| Blackstone | 12K | $171.3K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are SMMT's key statistics?
Key statistics as of Oct 22, 2026
SMMT price chart
Powered by TradingViewWhat does Summit Therapeutics Inc. do?
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly. Its lead candidate, ivonescimab, is a first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF pathways, advancing immunotherapy combined with anti-angiogenesis for oncology applications. The company is conducting multiple Phase III clinical trials evaluating ivonescimab, including in combination with chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) after third-generation TKI therapy, first-line metastatic NSCLC, squamous NSCLC, and first-line unresectable metastatic colorectal cancer. Summit Therapeutics Inc. also pursues collaborations, such as with GSK to combine ivonescimab with investigational therapies in solid tumors including small cell lung cancer. These efforts target serious unmet needs in oncology, particularly lung and colorectal cancers. Founded in 2003 and headquartered in Miami, Florida, Summit Therapeutics Inc. operates in the biotechnology sector with a pipeline centered on next-generation cancer treatments.